MARKET

GKOS

GKOS

Glaukos Corp
NYSE
124.79
+3.17
+2.61%
After Hours: 125.22 +0.43 +0.35% 17:48 04/17 EDT
OPEN
123.80
PREV CLOSE
121.62
HIGH
127.00
LOW
123.41
VOLUME
585.70K
TURNOVER
--
52 WEEK HIGH
130.23
52 WEEK LOW
73.16
MARKET CAP
7.25B
P/E (TTM)
-38.0237
1D
5D
1M
3M
1Y
5Y
1D
Assessing Glaukos (GKOS) Valuation After Recent Share Price Momentum
Simply Wall St · 1d ago
Glaukos receives permanent J-code for Epioxa
TipRanks · 4d ago
Glaukos Says CMS Assigns Permanent Healthcare Common Procedure Coding System J-Code For Epioxa HD / Epioxa For Treatment Of Keratoconus
Benzinga · 4d ago
Glaukos (GKOS) Receives a Buy from Mizuho Securities
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Verano Holdings (OtherVRNO), Community Health (CYH) and Glaukos (GKOS)
TipRanks · 6d ago
Weekly Report: what happened at GKOS last week (0406-0410)?
Weekly Report · 6d ago
William Blair med tech analyst holds an analyst/industry conference call
TipRanks · 04/10 17:00
Press Release: Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Dow Jones · 04/08 11:01
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.